Solventum Corporation (NYSE:SOLV) Stock Has Consensus Price Target of $92.80 According to Brokerages

Posted by Brenda Bartman on Sep 30th, 2026

Shares of Solventum Corporation (NYSE:SOLV – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $92.80.

SOLV has been the subject of a number of research reports. Wall Street Zen upgraded shares of Solventum from a “hold” rating to a “buy” rating in a research note on Saturday, September 12th. Wedbush upped their price target on shares of Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. BMO Capital Markets began coverage on shares of Solventum in a report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price target on the stock. Weiss Ratings upgraded shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Finally, UBS Group boosted their price objective on Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a report on Thursday, August 6th.

Check Out Our Latest Analysis on SOLV

Institutional Trading of Solventum

Several institutional investors have recently added to or reduced their stakes in SOLV. Sequoia Financial Advisors LLC grew its holdings in Solventum by 18.7% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 21,672 shares of the company’s stock valued at $1,672,000 after buying an additional 3,412 shares in the last quarter. MCF Advisors LLC lifted its holdings in shares of Solventum by 2,497.7% during the second quarter. MCF Advisors LLC now owns 1,143 shares of the company’s stock worth $88,000 after buying an additional 1,099 shares in the last quarter. WINTON GROUP Ltd bought a new stake in shares of Solventum in the second quarter valued at about $3,402,000. Engineers Gate Manager LP acquired a new position in shares of Solventum in the second quarter valued at about $1,881,000. Finally, Integrated Wealth Concepts LLC grew its stake in shares of Solventum by 7.1% in the second quarter. Integrated Wealth Concepts LLC now owns 9,052 shares of the company’s stock valued at $698,000 after acquiring an additional 597 shares in the last quarter.

Solventum Stock Down 0.2%

SOLV stock opened at $89.34 on Friday. Solventum has a 1-year low of $62.38 and a 1-year high of $94.16. The business’s 50 day simple moving average is $87.82 and its 200 day simple moving average is $78.06. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $15.21 billion, a PE ratio of 10.92, a PEG ratio of 1.40 and a beta of 0.61.

Solventum (NYSE:SOLV – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The firm had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.15 billion. During the same period in the previous year, the business posted $1.69 earnings per share. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, research analysts anticipate that Solventum will post 7.22 EPS for the current year.

About Solventum

(Get Free Report)

Solventum Corporation (NYSE:SOLV) is a global healthcare company that develops products, technologies and services designed to support clinical care, healthcare operations and patient outcomes. The company serves healthcare providers, dental professionals, laboratories, manufacturers and other organizations.

Solventum’s portfolio includes medical and surgical products such as wound-care systems, surgical drapes, sterilization and infection-prevention solutions, and patient-monitoring or fixation products.